Table 3.
Active Clinical trials in post-HCT relapse of AML/MDS.
| Study | Phase | No.patients | Intervention | Setting | Type |
|---|---|---|---|---|---|
| NCT03300492 | Phase 1/2 | 10 | Expanded NK cells in haploidentical HCT | Prophylactic | Prospective |
| NCT03597321 | Phase 2 | 124 | Early DLI after HCT | Prophylactic | Randomized |
| NCT02452697 | Phase 2 | 100 | NK-DLI +/- TLR9 agonist | Prophylactic | Randomized |
| NCT03939585 | Phase 1 | 10 | TCR-αβ T cells and B cells | Prophylactic | Single group assignment |
| NCT04173533 | Phase 3 | 324 | Oral AZA vs. Placebo | Prophylactic | Randomized |
| NCT02684162 | Phase 2 | 55 | Guadecitabine + DLI | Post-HCT relapse | Single group assignment |
| NCT04055844 | Phase 2 | 14 | Ruxolitinib+DEC+DLI | Post-HCT relapse | Multi-centre, single arm |
| NCT04857645 | Phase 2 | 40 | ASTX727+DLI | Prophylactic | Prospective |
| NCT05528354 | Phase 1 | 58 | VEN+DEC conditioning and DEC maintenance | Prophylactic | Multi-centre, single arm |
| NCT04674345 | Phase 2/3 | 346 | Sorafenib | Prophylactic | Multi-centre, prospective |
| NCT02997202 | Phase 3 | 356 | Gilteritinib | Prophylactic | Randomized, double-blind |
| NCT03515512 | Phase 1 | 23 | Evosidenib | Prophylactic | Single group assignment |
| NCT04522895 | Phase 2 | 50 | Enasidenib | Prophylactic | Multi-centre, prospective |
| NCT03728335 | Phase 1 | 15 | Enasidenib | Prophylactic | Single group assignment |
| NCT05447663 | Phase 1/2 | 32 | Siremadlin+/- DLI | Prophylactic | Single group assignment |
| NCT04623216 | Phase 1/2 | 59 | Sabatolimab | Treatment MRD | Randomized |
HCT, hematopoietic cell transplantation; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; VE; venetoclax; DEC, decitabine; AZA, azacytidine; MRD, minimal residual disease.